These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9891526)

  • 1. Puzzles in the clinical pharmacokinetics of fluorouracil.
    Desoize B; Bouche O; Berthiot G; Coninx P
    Anticancer Res; 1998; 18(6B):4607-10. PubMed ID: 9891526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil.
    Thiberville L; Compagnon P; Moore N; Bastian G; Richard MO; Hellot MF; Vincent C; Kannass MM; Dominique S; Thuillez C
    Cancer Chemother Pharmacol; 1994; 35(1):64-70. PubMed ID: 7987979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer.
    Jodrell DI; Stewart M; Aird R; Knowles G; Bowman A; Wall L; McLean C
    Br J Cancer; 2001 Mar; 84(5):600-3. PubMed ID: 11237378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil.
    Cascinu S; Aschele C; Barni S; Debernardis D; Baldo C; Tunesi G; Catalano V; Staccioli MP; Brenna A; Muretto P; Catalano G
    Clin Cancer Res; 1999 Aug; 5(8):1996-9. PubMed ID: 10473077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
    Di Paolo A; Danesi R; Vannozzi F; Falcone A; Mini E; Cionini L; Ibrahim T; Amadori D; Del Tacca M
    Clin Pharmacol Ther; 2002 Dec; 72(6):627-37. PubMed ID: 12496744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose and time dependencies of 5-fluorouracil pharmacokinetics.
    Terret C; Erdociain E; Guimbaud R; Boisdron-Celle M; McLeod HL; Féty-Deporte R; Lafont T; Gamelin E; Bugat R; Canal P; Chatelut E
    Clin Pharmacol Ther; 2000 Sep; 68(3):270-9. PubMed ID: 11014408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients.
    Hoshino S; Yamashita Y; Maekawa T; Shirakusa T
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):648-52. PubMed ID: 15959779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Possible effect of administration methods on pharmacological action. Study of cytostatic therapy in advanced cancer].
    Larsson PA; Carlsson G; Gustavsson B; Glimelius B; Graf W
    Lakartidningen; 1995 Dec; 92(50):4793-6. PubMed ID: 8538293
    [No Abstract]   [Full Text] [Related]  

  • 9. [Dose-intensive chemotherapy with continuous infusion 5-fluorouracil].
    Tichler T; Ghodsizade E; Katz A; Rath P; Berger R; Brenner H
    Harefuah; 1999 Nov; 137(9):387-90, 430. PubMed ID: 11419042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
    Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
    Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer].
    Faivre C; Rougier P; Ducreux M; Mitry E; Lusinchi A; Lasser P; Elias D; Eschwege F
    Bull Cancer; 1999 Oct; 86(10):861-5. PubMed ID: 10572237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer.
    Natoli C; Scognamiglio MT; Martino MT; Irtelli L; De Tursi M; Cianchetti E; Mascitelli E; Tinari N; Iacobelli S
    Anticancer Res; 2000; 20(2B):1253-6. PubMed ID: 10810430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination immunochemotherapy of 5-fluorouracil, cisplatin, leucovorin, and OK-432 for advanced and recurrent gastric carcinoma.
    Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Noguchi Y
    Hepatogastroenterology; 2003; 50(54):2259-63. PubMed ID: 14696512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104).
    Bavisotto LM; Patel NH; Althaus SJ; Coldwell DM; Nghiem HV; Thompson T; Storer B; Thomas CR
    Clin Cancer Res; 1999 Jan; 5(1):95-109. PubMed ID: 9918207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
    Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-FU split dose; a phase I/II and pharmacokinetic study of a different schedule of the Nordic regimen in advanced colorectal carcinoma.
    Berglund A; Carlsson G; Gustavsson B; Frödin JE; Ragnhammar P; Glimelius B
    Anticancer Res; 2003; 23(2C):1789-94. PubMed ID: 12820460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A comparison of 5-fluorouracil concentration of 5-fluorouracil drip infusion versus orally UFT in plasma of same patients].
    Hirata K; Sasaki K; Yamamitsu S; Shirasaka T
    Gan To Kagaku Ryoho; 1993 Aug; 20(10):1409-11. PubMed ID: 8346941
    [No Abstract]   [Full Text] [Related]  

  • 18. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
    Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
    Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
    Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
    Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
    Di Paolo A; Lencioni M; Amatori F; Di Donato S; Bocci G; Orlandini C; Lastella M; Federici F; Iannopollo M; Falcone A; Ricci S; Del Tacca M; Danesi R
    Clin Cancer Res; 2008 May; 14(9):2749-55. PubMed ID: 18451241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.